The call, on record
HIMS bullish call
Quoted text as recorded“But you start to add things like peptides to that, now you could potentially be going to 5 billion, maybe $6 billion worth of revenue in the next couple of years. Now you're at the point where you're at a price to sales multiple of getting close to one. And if you do reach those kind of sales numbers, your growth rate is going to continue to be somewhere around this 50% rate. That's a growth rate that deserves a much higher multiple.”@ 12:36 · open at this moment on YouTube ↗
Our interpretation
- Source published
- Nov 2, 2026
- Timeframe
- If revenue reaches $5–6 billion in the next couple of years and growth remains around 50%.
- Interpreted confidence
- low
- Specificity
- vague
Email me when HIMS calls resolve
When a tracked HIMS call is scored — hit, miss or partial — we’ll email you the result. No account needed.
Used only for these updates. Privacy
Our summary of the thesis
Strongly BullishStructured interpretation of the video, not a verbatim quotation. Check the source for conditions, emphasis and context.
The host argues that Hims & Hers combines leadership in a large addressable market with opportunities to expand products and geography. He views peptides as an additional growth engine that could make the current valuation particularly attractive, while acknowledging competition, regulatory uncertainty and international execution risk.
Key arguments
- The pharmaceutical market offers hundreds of billions of dollars in potential annual revenue.
- The cited market-share data position Hims & Hers as a leading telehealth provider.
- Additional specialties can attract new customers and increase spending by existing customers.
- International expansion broadens the addressable market and allows knowledge and branding to be shared across regions.
- Domestic peptide manufacturing could differentiate the company from competitors.
- Illustrative peptide subscriber scenarios suggest a potentially substantial incremental revenue stream.
- The host believes sustained growth would justify a higher valuation multiple.
Counter-arguments acknowledged
- Ro has spent heavily on expansion and gained share.
- International expansion gives management more responsibilities and introduces execution risk.
- Rules governing compounded peptides still need to be finalized.
- Competition could push peptide pricing lower.
- Revenue projections depend on assumptions about adoption and successful expansion.
Hedges and caveats (from the video)
- International expansion increases management complexity and execution risk.
- Ro has gained market share and could be closer to Hims & Hers than the cited data suggest.
- Peptide regulations remain unfinished, and Hims & Hers has not yet launched its offering.
- Peptide pricing, subscriber counts and revenue scenarios are illustrative estimates.
- Some revenue growth comes from acquisitions rather than organic expansion.
- Upcoming earnings will provide further evidence about the company's performance.
About this record
Not yet reviewed by a moderatorImported analysis · scheduled AI source. A quote, summary and outcome each need their own context. Moderator review does not certify investment performance.
- Source published
- Nov 2, 2026, 4:19 PM UTC
- First recorded by TubeRank
- Nov 2, 2026, 11:49 PM UTC
- Record last updated
- Nov 2, 2026, 11:49 PM UTC
- Moderator review recorded
- Not recorded
- Transcript provenance
- YouTube captions (manual or automatic)
- Recorded analysis processor/source label
- codex-cli-scheduled
- This can identify a workflow rather than an exact AI model version.
- Submission path version
- manual_v1
- Identifies the precomputed submission path. It does not identify an AI model version or imply human authorship.
- Outcome methodology version
- Not recorded; not audited under current rules
Recent record changes 1 shown
Nov 2, 2026, 11:49 PM UTC
source updated
- Recorded analysis processor/source label
BeforeNot recorded
Aftercodex-cli-scheduled
- Extraction or submission version
BeforeNot recorded
Aftermanual_v1
Showing up to 20 recent changes. The complete feed has 2 recorded events for this call, including its initial entry. Read the full paginated history (JSON); follow nextCursor while hasMore is true.
Stored outcome evidence
- Stored reference price
- Not recorded
- Not recorded · provider not recorded
- Target as extracted
- Not recorded
- Stated deadline as extracted
- None recorded
- Recorded outcome date
- Not recorded
- Outcome price observation
- Not recorded
- Not recorded · provider not recorded
Stored explanation
No explanation was recorded for this outcome.
Missing timestamps, providers and versions are historical gaps. Stored observations can include daily closes; they do not show every intraday touch or prove an executable trade. Read the methodology.
Why we interpreted the confidence this way
The host explicitly endorses a higher valuation multiple, but the case depends on illustrative revenue and sustained-growth assumptions and uses 'could potentially' and 'if'.